Freedom Capital Markets analyst Gene Mannheimer has initiated coverage on Tempus AI with a Hold rating and announced a price target of $59. The rating provides a benchmark for investors evaluating the stock's future performance relative to the set target.

Coverage Details

The initiation marks the firm's formal stance on Tempus AI, which trades on the NASDAQ under the ticker symbol TEM. The Hold rating suggests that the stock is expected to perform in line with the market or that investors should maintain their current positions.

Tempus AI has entered a research collaboration with Angiosarcoma Awareness to accelerate data-driven research in angiosarcoma, a rare malignant tumor known for its aggressive behavior and poor prognosis. The partnership aims to address the lack of molecular understanding and limited access to data that hinder research on rare cancers. By combining resources, the initiative seeks to identify biological patterns and potential therapeutic opportunities that are difficult to detect in smaller, fragmented datasets.

The collaboration will leverage Tempus’ robust datasets and compute and analytical resources to deepen understanding of angiosarcoma biology. This includes access to approximately 600 de-identified angiosarcoma records, each with paired DNA and RNA sequencing data. Associated de-identified clinical information is also included where available, creating one of the largest known disease-specific molecular datasets for angiosarcoma.

Angiosarcoma starts in endothelial cells, which form the inner lining of blood vessels, and is diagnosed in only about 1,000 people in the U.S. each year. Key challenges in studying rare cancers include the absence of effective pre-clinical models and the difficulty of detecting patterns in limited data. This initiative is designed to overcome those barriers by providing researchers with a comprehensive molecular and clinical dataset.

Key Data Components

The collaboration provides access to the following resources:

The dataset is expected to support researchers in identifying potential therapeutic opportunities and advancing the understanding of angiosarcoma biology.